S. 4189 · 119th Congress · Health
INSULIN Act of 2026
Unknown; bill summary not yet available. AI-read
- IntroducedMar 25, 2026 Done
- CommitteeReported Aug 7, 2026 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.Who lobbies on it
10 organizations, more than 96% of Senate bills · 14 filings · Q1 2026–Q3 2026These 10 organizations’ PACs gave $86.1K to 13 of the 29 members sponsoring or cosponsoring S. 4189 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
America's Health Insurance Plans Inc (ahip)
2 of 3 quarters
“…S. 4189 - INSULIN Act - Sen. Collins, Susan - Insulin cost-sharing caps S. 4512 - Affordable Insulin Now Act - Sen. Kennedy, John - Insulin cost-sharing caps Issues related to implementation rule implementing the No Surprises Act prohibiting surprise medical bills; transparency report requirements; parity in mental…”
$11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Pharmaceutical Care Management Association
2 of 3 quarters
“…Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570…”
$9.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Highmark Inc
2 of 3 quarters
“PBM Reform, transparency S. 1414, Expedited Access to Biosimilars Act - A bill to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. S.4189 - INSULIN Act of 2026…”
$780K lobbying spend in 2026 to date, all issuesQ3 2026 filing
7 more organizations, every filingPROUpgrade
Organizations that named S. 4189 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
5 actions · newest first- Aug 7, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 552.
- Aug 7, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 22, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Mar 25, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Show all 5 actionsShow fewer
- Mar 25, 2026Introduced in Senate
What members said about it
-
HYDE-SMITH COSPONSORS BIPARTISAN LEGISLATION TO CAP OUT-OF-POCKET INSULIN COSTS
Pocket Cost at $35, Reinforce Patient Protections WASHINGTON, D.C. – U.S. Senator Cindy Hyde-Smith (R-Miss.) on Tuesday agreed to cosponsor bipartisan legislation to lower the cost of insulin, reinforce patient protections, and make the…
“The INSULIN Act represents a strong, bipartisan effort to try to stop the unnecessary year-over-year increase in the price of insulin. Mississippians from across the state share their stories of their stress caused by insulin prices.”
-
INSULIN Act would limit out-of-pocket costs to $35 monthly
Legislation now in the U.S. Senate would lower the cost of insulin for patients with diabetes, as well as reinforce patient protections.
“The INSULIN Act represents a strong, bipartisan effort to try to stop the unnecessary year-over-year increase in the price of insulin. Mississippians from across the state share their stories of their stress caused by insulin prices.”